makes the selection on the basis of a growth of 57 per cent growth in revenue and 138 per cent in profit for the first half of this year. Considering the drug-maker’s closing price of N6.
09 at the last trading session, the stock is currently priced below its intrinsic value with a PE ratio of 6.66.NEM appears on the strength of its almost one-quarter expansion in sales and an increase of 29 per cent in profit at mid-year. The underwriter sees gross premium written rise to N25.5 billion and bottom-line to N4.1 billion come year end.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر: